FI3636274T3 - Koostumukset gamma-c-sytokiiniaktiivisuuden moduloimiseksi - Google Patents
Koostumukset gamma-c-sytokiiniaktiivisuuden moduloimiseksi Download PDFInfo
- Publication number
- FI3636274T3 FI3636274T3 FIEP19206731.2T FI19206731T FI3636274T3 FI 3636274 T3 FI3636274 T3 FI 3636274T3 FI 19206731 T FI19206731 T FI 19206731T FI 3636274 T3 FI3636274 T3 FI 3636274T3
- Authority
- FI
- Finland
- Prior art keywords
- amino acid
- peptide according
- group
- disease
- combination
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108010002335 Interleukin-9 Proteins 0.000 claims 2
- 206010044696 Tropical spastic paresis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims 1
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 claims 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims 1
- 101001055216 Homo sapiens Interleukin-9 Proteins 0.000 claims 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161433890P | 2011-01-18 | 2011-01-18 | |
| US201161527049P | 2011-08-24 | 2011-08-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3636274T3 true FI3636274T3 (fi) | 2024-10-25 |
Family
ID=46516044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19206731.2T FI3636274T3 (fi) | 2011-01-18 | 2012-01-17 | Koostumukset gamma-c-sytokiiniaktiivisuuden moduloimiseksi |
Country Status (19)
| Country | Link |
|---|---|
| US (10) | US9133244B2 (enExample) |
| EP (3) | EP2665486B1 (enExample) |
| JP (4) | JP6395379B2 (enExample) |
| CN (2) | CN109021069A (enExample) |
| AU (3) | AU2012207456C1 (enExample) |
| BR (1) | BR112013018046B1 (enExample) |
| CA (1) | CA2824515C (enExample) |
| CY (1) | CY1122846T1 (enExample) |
| DK (2) | DK3636274T3 (enExample) |
| ES (2) | ES2778053T3 (enExample) |
| FI (1) | FI3636274T3 (enExample) |
| HR (1) | HRP20200470T1 (enExample) |
| LT (1) | LT2665486T (enExample) |
| PL (2) | PL2665486T3 (enExample) |
| PT (2) | PT2665486T (enExample) |
| RS (1) | RS60050B1 (enExample) |
| SI (1) | SI2665486T1 (enExample) |
| SM (1) | SMT202000142T1 (enExample) |
| WO (1) | WO2012099886A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2778053T3 (es) | 2011-01-18 | 2020-08-07 | Bioniz Llc | Composiciones para modular la actividad de la citocina gamma-c |
| WO2015089217A2 (en) * | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| CN104789527B (zh) * | 2015-05-15 | 2018-05-29 | 江苏杰晟生物科技有限公司 | 一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品 |
| EP3359556B1 (en) | 2015-10-09 | 2021-05-26 | Bioniz, LLC | Modulating gamma - c -cytokine activity |
| US20190216898A1 (en) * | 2016-05-06 | 2019-07-18 | Wang Mulin | Interleukin Combination and Use Thereof |
| KR20240142577A (ko) * | 2017-04-07 | 2024-09-30 | 바이오니즈 테라퓨틱스, 아이엔씨. | 감마-c-사이토카인 활성의 안정한 조절자 |
| US20210269535A1 (en) * | 2018-07-19 | 2021-09-02 | The University Of Tokyo | Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham |
| CN112534052B (zh) | 2018-07-25 | 2024-09-20 | 奥美药业有限公司 | 全新il-21前药及使用方法 |
| KR20210055694A (ko) | 2018-08-06 | 2021-05-17 | 메디카인 인코포레이티드 | Il-2 수용체 결합 화합물 |
| CN121971599A (zh) | 2019-02-25 | 2026-05-05 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| JP2022530677A (ja) * | 2019-05-03 | 2022-06-30 | バイオニズ リミテッド ライアビリティー カンパニー | 脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節 |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| KR102265435B1 (ko) * | 2019-08-20 | 2021-06-15 | 주식회사 케어젠 | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 |
| KR20220110207A (ko) | 2019-11-05 | 2022-08-05 | 메디카인 인코포레이티드 | IL-2RβγC 결합 화합물 |
| IL292803A (en) | 2019-11-05 | 2022-07-01 | Medikine Inc | Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof |
| JP7767290B2 (ja) | 2020-01-11 | 2025-11-11 | アスクジーン・ファーマ・インコーポレイテッド | 新規なマスクされたサイトカインおよびその使用方法 |
| CA3169452A1 (en) | 2020-02-03 | 2021-08-12 | Medikine, Inc. | Il-7r.alpha. binding compounds |
| US11746139B2 (en) | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
| JP2023520922A (ja) | 2020-04-10 | 2023-05-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能サイトカイン構築物および関連組成物ならびに方法 |
| US20230338473A1 (en) * | 2020-06-24 | 2023-10-26 | Bioniz, Llc | Antagonistic peptide targeting il-2, il-9, and il-15 signaling for the treatment of cytokinerelease syndrome and cytokine storm associated disorders |
| EP4212163A4 (en) | 2020-09-08 | 2024-09-18 | Dexon Pharmaceuticals Inc. | CYTOKINE STORM INHIBITOR, METHOD FOR USING CYTOKINE STORM INHIBITOR, AND METHOD FOR SCREENING CYTOKINE INHIBITOR |
| CA3211924A1 (en) | 2021-03-16 | 2022-09-22 | Sayantan Mitra | Masked activatable cytokine constructs and related compositions and methods |
| JP6974892B1 (ja) | 2021-05-27 | 2021-12-01 | デクソンファーマシューティカルズ株式会社 | 癌悪液質の改善剤および癌悪液質の改善方法 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5700913A (en) | 1982-12-15 | 1997-12-23 | Ajinomoto Co., Inc. | Unglycosylated human interleukin-2 polypeptides |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| IL80678A (en) | 1985-11-19 | 1999-05-09 | Schering Biotech Corp | Human interleukin-4 |
| US6028186A (en) | 1991-06-10 | 2000-02-22 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of cytokines |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US6037149A (en) | 1995-08-24 | 2000-03-14 | Magainin Pharmaceuticals Inc. | DNA encoding human asthma associated factor 1 |
| IL130238A0 (en) | 1999-06-01 | 2000-06-01 | Peptor Ltd | Conformationally constrained backbone cyclized interleukin-6 antagonists |
| CA2253942A1 (en) | 1996-05-10 | 1997-11-20 | Biogen, Inc. | Common gamma chain blocking agents |
| US6127387A (en) | 1996-12-10 | 2000-10-03 | Thomas Jefferson University | Use of CD4-binding small molecules to inhibit immune responses |
| CN1269805A (zh) * | 1997-07-14 | 2000-10-11 | 博尔德生物技术公司 | 生长激素和相关蛋白的衍生物 |
| US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US6861227B2 (en) | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| EP0972780A1 (en) * | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| AU2001261585B2 (en) | 2000-05-12 | 2006-08-31 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
| DE60138222D1 (de) * | 2000-09-14 | 2009-05-14 | Beth Israel Hospital | Modulierung von il-2 und il-15 vermittelten t zellantworten |
| MXPA03003407A (es) * | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
| US20040126900A1 (en) | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
| CA2452372A1 (en) | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| CA2465268A1 (en) | 2001-10-24 | 2003-05-01 | National Jewish Medical And Research Center | Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto |
| MXPA04004167A (es) * | 2001-11-05 | 2004-07-08 | Zymogenetics Inc | Antagonistas de interleucina-21. |
| ES2382800T3 (es) | 2002-01-18 | 2012-06-13 | Zymogenetics, Inc. | Multímeros Zcytor17 receptores de citocinas |
| US20050063947A1 (en) | 2002-03-27 | 2005-03-24 | Patrick Hwu | Method for treating cancer in humans |
| WO2003087320A2 (en) * | 2002-04-09 | 2003-10-23 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
| JP2005525404A (ja) | 2002-05-01 | 2005-08-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｉｖ感染およびａｉｄｓを処置するためにサイトカインアンタゴニストを使用する方法 |
| DK1531850T3 (da) * | 2002-06-07 | 2012-06-04 | Zymogenetics Inc | Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere |
| WO2004002500A1 (en) | 2002-06-28 | 2004-01-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| AU2003251633A1 (en) | 2002-07-01 | 2004-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Il-21 as a regulator of immunoglobin production |
| CN1688340A (zh) | 2002-07-15 | 2005-10-26 | 韦思公司 | 调节t辅助(th)细胞发育和功能的方法和组合物 |
| US20060236411A1 (en) * | 2002-10-14 | 2006-10-19 | Ingeborg Dreher | Antagonists il-15 |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| AU2004224277A1 (en) | 2003-03-21 | 2004-10-07 | Wyeth | Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor |
| EP1622568B1 (en) | 2003-05-14 | 2010-07-07 | Bayer Pharmaceuticals Corporation | Interleukin-9 antagonist muteins and their pharmacological methods of use |
| CA2529520A1 (en) | 2003-06-19 | 2004-12-29 | Centocor, Inc. | Interleukin-21 analogs |
| DE602004031681D1 (de) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7785580B2 (en) | 2003-08-29 | 2010-08-31 | Aerovance, Inc. | Modified IL-4 mutein receptor antagonists |
| JP2007506789A (ja) | 2003-09-25 | 2007-03-22 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１を用いた自己免疫疾患の治療方法 |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| EP1708737A2 (en) | 2004-01-15 | 2006-10-11 | Novo Nordisk A/S | Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection |
| ES2395087T3 (es) | 2004-05-05 | 2013-02-08 | Valorisation-Recherche, Société en Commandite | Antagonistas del receptor de interleuquina-1, composiciones y métodos de tratamiento |
| US20060024268A1 (en) | 2004-05-19 | 2006-02-02 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
| CA2574848A1 (en) | 2004-08-05 | 2006-12-21 | Wyeth | Antagonizing interleukin-21 receptor activity |
| CU23472A1 (es) * | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
| WO2006105538A2 (en) | 2005-03-31 | 2006-10-05 | Centocor, Inc. | Methods and compositions for treating il-21 related pathologies |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| MX2007012887A (es) | 2005-04-18 | 2007-12-10 | Novo Nordisk As | Variantes il-21. |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| EP1940734A2 (en) * | 2005-08-10 | 2008-07-09 | Northwestern University | Composite particles |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP2805971A1 (en) | 2005-11-28 | 2014-11-26 | ZymoGenetics, Inc. | IL-21 antagonists |
| WO2008031064A1 (en) | 2006-09-07 | 2008-03-13 | University Of South Florida | Hyd1 peptides as anti-cancer agents |
| WO2008049920A2 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
| WO2008074863A1 (en) | 2006-12-21 | 2008-06-26 | Novo Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
| US7910123B2 (en) | 2007-09-05 | 2011-03-22 | Warsaw Orthopedic | Methods of treating a trauma or disorder of the knee joint by local administration and sustained-delivery of a biological agent |
| WO2009100035A2 (en) | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| WO2009108341A1 (en) | 2008-02-28 | 2009-09-03 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
| WO2009132821A1 (en) | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| EP2303353B1 (en) * | 2008-06-12 | 2018-01-10 | Ramot at Tel-Aviv University Ltd. | Drug-eluting medical devices |
| US20110144306A1 (en) | 2008-07-23 | 2011-06-16 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| US20100075329A1 (en) | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
| CA2743394C (en) | 2008-11-17 | 2018-01-02 | Koebenhavns Universitet | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
| WO2010076339A1 (en) | 2009-01-05 | 2010-07-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Means and method for the treatment of antibody deficiency diseases based on il-21 and il-21 variants |
| TW201613969A (en) | 2009-03-05 | 2016-04-16 | Abbvie Inc | IL-17 binding proteins |
| WO2010103038A1 (en) | 2009-03-11 | 2010-09-16 | Novo Nordisk A/S | Interleukin-21 variants having antagonistic binding to the il-21 receptor |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| BR112012000867A2 (pt) | 2009-07-13 | 2019-09-24 | Harvard College | "polipeptídeos bifuncional costurado e uso do mesmo" |
| EP2511294B1 (en) | 2009-12-11 | 2014-02-26 | Proyecto de Biomedicina Cima, S.L. | Conjugates and compositions for immunotherapy and anti-tumoral treatment |
| JP5835741B2 (ja) * | 2010-02-26 | 2015-12-24 | 国立大学法人 長崎大学 | 抗原または薬物送達複合体 |
| US9782454B2 (en) | 2010-04-22 | 2017-10-10 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| US8822642B2 (en) | 2010-06-09 | 2014-09-02 | Zymogenetics, Inc. | Dimeric fusion proteins and related compositions and methods |
| US9084761B2 (en) * | 2010-07-09 | 2015-07-21 | The Regents Of The University Of California | Use of interleukin-15 to treat cardiovascular diseases |
| WO2012012531A2 (en) | 2010-07-20 | 2012-01-26 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods featuring il-6 and il-21 antagonists |
| ES2778053T3 (es) | 2011-01-18 | 2020-08-07 | Bioniz Llc | Composiciones para modular la actividad de la citocina gamma-c |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US9670672B2 (en) | 2014-12-03 | 2017-06-06 | Aleksandar Stevanov | Roof panel system |
| JP6800219B2 (ja) | 2015-09-16 | 2020-12-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用 |
| US20170104927A1 (en) | 2015-10-07 | 2017-04-13 | Little Star Media, Inc. | Systems, methods and software programs for 360 degree video distribution platforms |
| EP3359556B1 (en) | 2015-10-09 | 2021-05-26 | Bioniz, LLC | Modulating gamma - c -cytokine activity |
| SG11201903882VA (en) | 2016-11-08 | 2019-05-30 | Delinia Inc | Il-2 variants for the treatment of autoimmune diseases |
| KR20240142577A (ko) | 2017-04-07 | 2024-09-30 | 바이오니즈 테라퓨틱스, 아이엔씨. | 감마-c-사이토카인 활성의 안정한 조절자 |
| JP2022530677A (ja) | 2019-05-03 | 2022-06-30 | バイオニズ リミテッド ライアビリティー カンパニー | 脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節 |
-
2012
- 2012-01-17 ES ES12736203T patent/ES2778053T3/es active Active
- 2012-01-17 ES ES19206731T patent/ES2989085T3/es active Active
- 2012-01-17 DK DK19206731.2T patent/DK3636274T3/da active
- 2012-01-17 LT LTEP12736203.6T patent/LT2665486T/lt unknown
- 2012-01-17 CA CA2824515A patent/CA2824515C/en active Active
- 2012-01-17 PL PL12736203T patent/PL2665486T3/pl unknown
- 2012-01-17 SI SI201231746T patent/SI2665486T1/sl unknown
- 2012-01-17 FI FIEP19206731.2T patent/FI3636274T3/fi active
- 2012-01-17 EP EP12736203.6A patent/EP2665486B1/en active Active
- 2012-01-17 EP EP19206731.2A patent/EP3636274B1/en active Active
- 2012-01-17 DK DK12736203.6T patent/DK2665486T3/da active
- 2012-01-17 RS RS20200324A patent/RS60050B1/sr unknown
- 2012-01-17 WO PCT/US2012/021566 patent/WO2012099886A1/en not_active Ceased
- 2012-01-17 PT PT127362036T patent/PT2665486T/pt unknown
- 2012-01-17 PL PL19206731.2T patent/PL3636274T3/pl unknown
- 2012-01-17 BR BR112013018046-3A patent/BR112013018046B1/pt not_active IP Right Cessation
- 2012-01-17 CN CN201810863447.XA patent/CN109021069A/zh active Pending
- 2012-01-17 JP JP2013550541A patent/JP6395379B2/ja active Active
- 2012-01-17 HR HRP20200470TT patent/HRP20200470T1/hr unknown
- 2012-01-17 SM SM20200142T patent/SMT202000142T1/it unknown
- 2012-01-17 US US13/980,305 patent/US9133244B2/en active Active
- 2012-01-17 AU AU2012207456A patent/AU2012207456C1/en not_active Ceased
- 2012-01-17 EP EP24188657.1A patent/EP4461742A3/en active Pending
- 2012-01-17 CN CN201280010348.8A patent/CN103501805B/zh not_active Expired - Fee Related
- 2012-01-17 PT PT192067312T patent/PT3636274T/pt unknown
- 2012-08-17 US US13/589,017 patent/US8455449B2/en not_active Expired - Fee Related
-
2013
- 2013-04-23 US US13/868,725 patent/US9133243B2/en active Active
-
2015
- 2015-09-11 US US14/852,240 patent/US9675672B2/en not_active Expired - Fee Related
-
2016
- 2016-06-10 US US15/179,900 patent/US9951105B2/en active Active
-
2017
- 2017-01-25 AU AU2017200489A patent/AU2017200489B2/en not_active Ceased
- 2017-03-30 US US15/474,312 patent/US10227382B2/en active Active
- 2017-04-28 JP JP2017090501A patent/JP6820230B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-19 US US15/957,806 patent/US10808009B2/en active Active
-
2019
- 2019-03-06 US US16/294,733 patent/US11834519B2/en active Active
- 2019-04-11 AU AU2019202527A patent/AU2019202527B2/en not_active Ceased
- 2019-08-23 JP JP2019152602A patent/JP2020002154A/ja active Pending
-
2020
- 2020-03-20 CY CY20201100269T patent/CY1122846T1/el unknown
- 2020-09-04 US US17/012,724 patent/US11708392B2/en active Active
-
2023
- 2023-11-06 US US18/502,536 patent/US20240209025A1/en not_active Abandoned
-
2024
- 2024-01-04 JP JP2024000335A patent/JP2024029182A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200470T1 (hr) | Pripravci za modulaciju aktivnosti gama-c-citokina | |
| JP2020002154A5 (enExample) | ||
| JP7623272B2 (ja) | 持続的エピジェネティック遺伝子サイレンシング | |
| Culley | Natural killer cells in infection and inflammation of the lung | |
| Schreiner et al. | CD4+ memory T cells at home in the tissue: mechanisms for health and disease | |
| JP2024029182A5 (enExample) | ||
| Kim et al. | Innate lymphoid cells and allergic inflammation | |
| Liao et al. | IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation | |
| Schultz-Cherry | Role of NK cells in influenza infection | |
| JP2015134796A5 (enExample) | ||
| IN2014CN03937A (enExample) | ||
| WO2010148335A3 (en) | Structured viral peptide compositions and methods of use | |
| WO2011123830A3 (en) | Alpha 1-antitrypsin compositions and methods of making and using same | |
| JP2009508471A5 (enExample) | ||
| JP2020513020A5 (enExample) | ||
| Son et al. | Co-ordination of mucosal B cell and CD8 T cell memory by tissue-resident CD4 helper T cells | |
| MX2022002637A (es) | Proteinas de fusion terapeuticas. | |
| IN2015DN00585A (enExample) | ||
| JP2020513810A5 (enExample) | ||
| Sisto et al. | Targeting interleukin-17 as a novel treatment option for fibrotic diseases | |
| Spolski et al. | IL-21 promotes the pathologic immune response to pneumovirus infection | |
| Wang et al. | Characterisation of IL-15 and IL-2Rβ in grass carp: IL-15 upregulates cytokines and transcription factors of type 1 immune response and NK cell activation | |
| EP2928916A1 (en) | Novel interleukin-33 inhibitors | |
| Caccia et al. | Antimicrobial peptides are expressed during early development of zebrafish (Danio rerio) and are inducible by immune challenge | |
| JP2016516054A5 (enExample) |